ClinConnect ClinConnect Logo
Search / Trial NCT03483337

New MRI Biomarkers in Head and Neck Cancers

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 23, 2018

Trial Information

Current as of September 11, 2025

Recruiting

Keywords

(Dw) Mri Oncological Biomarkers Metastatic Recurrent 18 063

ClinConnect Summary

This clinical trial is investigating new ways to use MRI (Magnetic Resonance Imaging) to learn more about head and neck cancers, including thyroid cancer. MRI is a safe imaging technique that uses magnetic fields and radio waves to create detailed pictures of the body, helping doctors see tumors and other important areas. The study specifically focuses on a type of MRI called diffusion MRI, which measures how water moves in tumors. Researchers hope this new information will improve how we understand and treat these cancers.

To participate in this trial, you need to be at least 18 years old and have a suspicious or confirmed case of head and neck cancer or thyroid cancer. You should also be planning to receive treatment at Memorial Sloan Kettering (MSK). However, some people cannot join, including those who are claustrophobic, require anesthesia for the MRI, have certain medical implants, or are pregnant. If you participate, you can expect to undergo an MRI scan, which is a painless procedure. This study aims to provide better insights into your condition, potentially leading to improved treatment options in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years
  • Group 1 patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region.
  • * Group 2 patients:
  • Biopsy proven recurrent or metastatic or definitive head and neck cancer or (differentiated and undifferentiated) thyroid cancers in the head and neck region only.
  • Patients planning to undergo reatment at MSK
  • Exclusion Criteria:
  • Patient would require anesthesia for the study
  • Patients who are claustrophobic
  • Patients selecting treatment outside of MSK
  • Known reaction to Gd based contrast agent
  • Patients who have presence of a known contradiction to MRI
  • Pacemaker
  • Aneurysm clips
  • Patients with implants that are contradicted for MR imaging will be excluded
  • Pregnant
  • Age and mental status wherein he /she is unable to cooperate for MRI study

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Amita Dave, PhD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials